Upgrades Archives - Page 99 of 188

2 minute read

Why This Shopify Analyst Says ‘A Premium Is Warranted’ Following Price Increases And A Merchant Survey

January 30, 1:34 PM

Shopify Inc (NYSE: SHOP) shares jumped last week after the company raised prices on all of its plans following 12 years of largely unchanged pricing. Roth Capital turned more positive on the stock in the w

SHOP

1 minute read

Compass Point Upgrades Federal Realty Investment to Buy, Announces $125 Price Target

By Benzinga Newsdesk

January 30, 9:29 AM

Compass Point analyst Floris Van Dijkum upgrades Federal Realty Investment (NYSE:FRT) from Neutral to Buy and announces $125 price target.

FRT

1 minute read

DZ Bank Upgrades Lockheed Martin to Buy, Announces $523 Price Target

By Benzinga Newsdesk

January 30, 9:13 AM

DZ Bank analyst Robert Czerwensky upgrades Lockheed Martin (NYSE:LMT) from Hold to Buy and announces $523 price target.

LMT

1 minute read

Roth Capital Upgrades Shopify to Buy, Raises Price Target to $56

By Benzinga Newsdesk

January 30, 9:08 AM

Roth Capital analyst Darren Aftahi upgrades Shopify (NYSE:SHOP) from Neutral to Buy and raises the price target from $38 to $56.

SHOP

1 minute read

Morgan Stanley Upgrades Colgate-Palmolive to Overweight, Maintains $82 Price Target

By Benzinga Newsdesk

January 30, 7:53 AM

Morgan Stanley analyst Dara Mohsenian upgrades Colgate-Palmolive (NYSE:CL) from Equal-Weight to Overweight and maintains $82 price target.

1 minute read

Berenberg Upgrades Tesla to Buy, Lowers Price Target to $200

By Benzinga Newsdesk

January 30, 6:27 AM

Berenberg analyst Adrian Yanoshik upgrades Tesla (NASDAQ:TSLA) from Hold to Buy and lowers the price target from $255 to $200.

TSLA

1 minute read

Credit Suisse Upgrades Kemper to Neutral, Raises Price Target to $56

By Benzinga Newsdesk

January 30, 6:17 AM

Credit Suisse analyst Andrew Kligerman upgrades Kemper (NYSE:KMPR) from Underperform to Neutral and raises the price target from $44 to $56.

KMPR

1 minute read

JP Morgan Upgrades G1 Therapeutics to Neutral, Raises Price Target to $10

By Benzinga Newsdesk

January 30, 6:16 AM

JP Morgan analyst Anupam Rama upgrades G1 Therapeutics (NASDAQ:GTHX) from Underweight to Neutral and raises the price target from $7 to $10.

GTHX

1 minute read

Pet Sector Gets Some Love From This Analyst: Expect ‘Solid’ Earnings From Chewy

By Priya Nigam

January 27, 11:16 AM

Shares of Chewy Inc (NYSE: CHWY) have been on an uptrend year to date, reversing losses made after the company’s fiscal third-quarter earnings.

CHWY

1 minute read

Morgan Stanley Upgrades Vir Biotechnology to Equal-Weight, Raises Price Target to $30

By Benzinga Newsdesk

January 27, 7:28 AM

Morgan Stanley analyst Michael Ulz upgrades Vir Biotechnology (NASDAQ:VIR) from Underweight to Equal-Weight and raises the price target from $18 to $30.

VIR